Pathophysiological pathway differences in children who present with COVID-19 ARDS compared to COVID -19 induced MIS-C

Conor McCafferty, Tengyi Cai, Delphine Borgel, Dominique Lasne, Sylvain Renolleau, Meryl Vedrenne-Cloquet, Damien Bonnet, Jemma Wu, Thiri Zaw, Atul Bhatnagar, Xiaomin Song, Suelyn Van Den Helm, Natasha Letunica, Chantal Attard, Vasiliki Karlaftis, Slavica Praporski, Vera Ignjatovic, Paul Monagle, Conor McCafferty, Tengyi Cai, Delphine Borgel, Dominique Lasne, Sylvain Renolleau, Meryl Vedrenne-Cloquet, Damien Bonnet, Jemma Wu, Thiri Zaw, Atul Bhatnagar, Xiaomin Song, Suelyn Van Den Helm, Natasha Letunica, Chantal Attard, Vasiliki Karlaftis, Slavica Praporski, Vera Ignjatovic, Paul Monagle

Abstract

COVID-19 has infected more than 275 million worldwide (at the beginning of 2022). Children appear less susceptible to COVID-19 and present with milder symptoms. Cases of children with COVID-19 developing clinical features of Kawasaki-disease have been described. Here we utilise Mass Spectrometry proteomics to determine the plasma proteins expressed in healthy children pre-pandemic, children with multisystem inflammatory syndrome (MIS-C) and children with COVID-19 induced ARDS. Pathway analyses were performed to determine the affected pathways. 76 proteins are differentially expressed across the groups, with 85 and 52 proteins specific to MIS-C and COVID-19 ARDS, respectively. Complement and coagulation activation are implicated in these clinical phenotypes, however there was significant contribution of FcGR and BCR activation in MIS-C and scavenging of haem and retinoid metabolism in COVID-19 ARDS. We show global proteomic differences in MIS-C and COVID-ARDS, although both show complement and coagulation dysregulation. The results contribute to our understanding of MIS-C and COVID-19 ARDS in children.

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s).

Figures

Fig. 1. Hierarchical clustering of all detected…
Fig. 1. Hierarchical clustering of all detected proteins.
a Unsupervised hierarchical clustering analysis for the 319 protein identifications using the local assay library. Relative expression patterns obtained using Euclidean distance; Green: proteins with decreased expression; Red: proteins with increased expression; b Principal Component Analysis of data from a. The axis of PC1, PC2 and PC3 represented the first three principal components.
Fig. 2. Overall differentially expressed proteins.
Fig. 2. Overall differentially expressed proteins.
a Heatmap of the 76 differentially expressed proteins from the local assay library identified using unadjusted p value and fold-change with two-sided t test. The clustering patterns were obtained using a Euclidean-based distance and complete linkage; Green: proteins with decreased expression; Red: proteins with increased expression; b Heatmap of the 44 differentially expressed proteins from the local assay library identified using p values adjusted for multiple comparisons by using two-sided t test with Benjamini-Hochberg correction.
Fig. 3. Enriched pathways between COVID-19 ARDS…
Fig. 3. Enriched pathways between COVID-19 ARDS and Healthy Group.
Top 10 enriched pathways for the 52 differentially expressed proteins based on the unadjusted p value and fold-change comparison between COVID-19 ARDS Group and Healthy Group, ranked in increasing order of their p values (determined using two-sided t test) from left-to-right. (a Reactome pathway analysis; b STRING pathway analysis). Top 10 enriched pathways for the 17 differentially expressed proteins based on the adjusted p value (using two-sided t test adjusted for multiple comparison with Benjamini-Hochberg correction) comparison between COVID-19 ARDS Group and Healthy Group, ranked in increasing order of their p values from left-to-right. (c Reactome pathway analysis; d STRING pathway analysis). The size of the bar in each graph indicates the proportion of proteins in that pathway that are up- or down-regulated in our study, the number reported at the top of each bar is the specific number of proteins in that pathway affected. Dark grey: proteins with relative increased expression in COVID-19 ARDS Group; Light grey: proteins with relative decreased expression in COVID-19 ARDS Group. Black line with a white circle: -Log10 (p value). Indicated pathways suggest biological pathways that are most impacted as a result of COVID-19 ARDS.
Fig. 4. Enriched pathways between MIS-C and…
Fig. 4. Enriched pathways between MIS-C and Healthy Group.
Top ten enriched pathways for the 85 differentially expressed proteins based on the unadjusted p value and fold change comparison between MIS-C Group and Healthy Group, ranked in increasing order of their p values (determined using two-sided t test) from left-to-right. (a Reactome pathway analysis; b STRING pathway analysis). Top 10 enriched pathways for the 26 differentially expressed proteins based on the adjusted p value (using two-sided t test adjusted for multiple comparisons with Benjamini-Hochberg correction) comparison between MIS-C Group and Healthy Group, ranked in increasing order of their p values from left to right. (c Reactome pathway analysis; d STRING pathway analysis). The size of the bar in each graph indicates the proportion of proteins in that pathway that are up- or down-regulated in our study, the number reported at the top of each bar is the specific number of proteins in that pathway affected. Light grey: proteins with relative decreased expression in MIS-C Group; Dark grey: proteins with relative increased expression in MIS-C Group; Black line with a white circle: -Log10 (p value); Number in each column represents the total proteins number of the pathway. Indicated pathways suggest biological pathways that are most impacted as a result of COVID-19 ARDS.

References

    1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 2020;20:533–534. doi: 10.1016/S1473-3099(20)30120-1.
    1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Wkly. 2020;2:113–122. doi: 10.46234/ccdcw2020.032.
    1. Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J. Pediatr. 87, 1–6 (2020).
    1. Rothe C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N. Engl. J. Med. 2020;382:970–971. doi: 10.1056/NEJMc2001468.
    1. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.. doi: 10.1016/S0140-6736(20)30566-3.
    1. World Health Organisation. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). (WHO, 2020).
    1. Lu X, et al. SARS-CoV-2 infection in children. N. Engl. J. Med. 2020;382:1663–1665. doi: 10.1056/NEJMc2005073.
    1. Bialek S, et al. Coronavirus Disease 2019 in Children—United States, February 12–April 2, 2020. Morbid. Mortal. Wkly. Rep. 2020;69:422–426. doi: 10.15585/mmwr.mm6914e4.
    1. World Health Organization. Novel coronavirus. (2020).
    1. Jiehao C, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin. Infect. Dis. 2020;71:1547–51.. doi: 10.1093/cid/ciaa198.
    1. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607–1608. doi: 10.1016/S0140-6736(20)31094-1.
    1. Jones VG, et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp. Pediatr. 2020;10:537–540. doi: 10.1542/hpeds.2020-0123.
    1. Verdoni L, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395:1771–1778. doi: 10.1016/S0140-6736(20)31103-X.
    1. Grimaud M, et al. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Ann. Intensive Care. 2020;10:69. doi: 10.1186/s13613-020-00690-8.
    1. Whittaker E. et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 324, 259–269 (2020).
    1. Capone CA, et al. Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 Infection. J. Pediatr. 2020;224:141–145. doi: 10.1016/j.jpeds.2020.06.044.
    1. Paediatrics RCo, Health C. Guidance-Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. College Reino Unido (2020).
    1. Pouletty M, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann. Rheum. Dis. 2020;79:999–1006. doi: 10.1136/annrheumdis-2020-217960.
    1. Toubiana, J. et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 369, m2094 (2020).
    1. Belhadjer Z, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation. 2020;142:429–436. doi: 10.1161/CIRCULATIONAHA.120.048360.
    1. Ramcharan T., et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric hospital. Pediatr Cardiol. 41, 1391–1401 (2020).
    1. Messner, C. B. et al. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst. 11, 11–24 (2020).
    1. Shen B, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182:59–72.e15. doi: 10.1016/j.cell.2020.05.032.
    1. Diorio C, et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020;4:6051–6063. doi: 10.1182/bloodadvances.2020003471.
    1. Matsushita M, et al. Activation of the lectin complement pathway by H-ficolin (Hakata antigen) J. Immunol. 2002;168:3502–3506. doi: 10.4049/jimmunol.168.7.3502.
    1. Holter JC, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc. Natl Acad. Sci. 2020;117:25018–25025. doi: 10.1073/pnas.2010540117.
    1. Al‐Ghafry M, et al. Are children with SARS‐CoV‐2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients. Pediatr. Blood Cancer. 2020;67:e28737. doi: 10.1002/pbc.28737.
    1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020;18:844–847. doi: 10.1111/jth.14768.
    1. Nagelkerke SQ, Kuijpers TW. Immunomodulation by IVIg and the role of FC-gamma receptors: classic mechanisms of action after all? Front. Immunol. 2015;5:674. doi: 10.3389/fimmu.2014.00674.
    1. Harwood, R. et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health.5, 133–141 (2021).
    1. Paoli M, Marles-Wright J, Smith A. Structure–function relationships in heme-proteins. DNA Cell Biol. 2002;21:271–280. doi: 10.1089/104454902753759690.
    1. Ascenzi P, et al. Hemoglobin and heme scavenging. IUBMB Life. 2005;57:749–759. doi: 10.1080/15216540500380871.
    1. Gaggar A, Patel RP. There is blood in the water: hemolysis, hemoglobin, and heme in acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 2016;311:L714–l8. doi: 10.1152/ajplung.00312.2016.
    1. Sarohan AR. COVID-19: endogenous retinoic acid theory and retinoic acid depletion syndrome. Med. Hypotheses. 2020;144:110250. doi: 10.1016/j.mehy.2020.110250.
    1. Kell AM, Gale M., Jr. RIG-I in RNA virus recognition. Virology. 2015;479-480:110–121. doi: 10.1016/j.virol.2015.02.017.
    1. Dowell SF, et al. Treatment of respiratory syncytial virus infection with vitamin A: a randomized, placebo-controlled trial in Santiago, Chile. Pediatr. Infect. Dis. J. 1996;15:782–786. doi: 10.1097/00006454-199609000-00009.
    1. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. Pediatr. Crit Care Med. 16:428–439 (2015).
    1. Hoq M, et al. A prospective, cross-sectional study to establish age-specific reference intervals for neonates and children in the setting of clinical biochemistry, immunology and haematology: the HAPPI Kids study protocol. BMJ Open. 2019;9:e025897. doi: 10.1136/bmjopen-2018-025897.
    1. Wu JX, et al. SWATH mass spectrometry performance using extended peptide MS/MS assay libraries. Mol. Cell Proteom. 2016;15:2501–2514. doi: 10.1074/mcp.M115.055558.
    1. Fabregat A, et al. Reactome pathway analysis: a high-performance in-memory approach. BMC Bioinform. 2017;18:142. doi: 10.1186/s12859-017-1559-2.
    1. Szklarczyk D, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447–D452. doi: 10.1093/nar/gku1003.

Source: PubMed

3
Abonnieren